Organometallic gold(I) and gold(III) complexes for lung cancer treatment

Juzheng Zhang; Yanping Li; Ronghao Fang; Wei Wei; Yong Wang; Jiamin Jin; Feng Yang; Jian Chen

doi:10.3389/fphar.2022.979951

Organometallic gold(I) and gold(III) complexes for lung cancer treatment

Front Pharmacol. 2022 Sep 13:13:979951. doi: 10.3389/fphar.2022.979951. eCollection 2022.

Authors

Juzheng Zhang¹, Yanping Li², Ronghao Fang¹, Wei Wei¹, Yong Wang¹, Jiamin Jin¹, Feng Yang³, Jian Chen¹

Affiliations

¹ Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.
² School of Public Health, Guilin Medical University, Guilin, China.
³ State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, China.

Abstract

Metal compounds, especially gold complexes, have recently gained increasing attention as possible lung cancer therapeutics. Some gold complexes display not only excellent activity in cisplatin-sensitive lung cancer but also in cisplatin-resistant lung cancer, revealing promising prospects in the development of novel treatments for lung cancer. This review summarizes examples of anticancer gold(I) and gold (III) complexes for lung cancer treatment, including mechanisms of action and approaches adopted to improve their efficiency. Several excellent examples of gold complexes against lung cancer are highlighted.

Keywords: A549; Gold(I) complexes; anticancer; gold(III) complexes; lung cancer.

Publication types

Review